J-Startup is a program promoted by the Ministry of Economy, Trade and Industry in Japan to support and train startup companies. The program aims to create successful and cutting-edge Japanese startups that can compete globally and bring new value to the world.

Rege Nephro Co., Ltd.

J-Startup

Rege Nephro is a clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease (ADPKD), and founded in 2019.
There are 13 million patients with CKD in Japan, of which 340,000 are severe CKD patients forced to undergo artificial dialysis. The healthcare cost of dialysis is $12 billion, 4% of the total healthcare cost of Japan.
However, there is still no curative treatment for CKD. Rege Nephro tries to treat patients suffering from CKD with cell therapy using nephron progenitor cells differentiated from iPS cells.

Fujifilm

JAFCO

Japan Science and Technology Agency

Kyogin Lease & Capital

Kyoto University Innovation Capital

Healthcare Innovation

We are pleased to announce the signing of a licensing agreement for non-exclusive implementation of patents related to C4U and CRISPR-Cas3 technologies. This agreement allows us to move forward with our innovations and developments. We look forward to further advancements and collaborations in the future!
https://lnkd.in/gQVigBEt

GO

JP:GO:J-STARTUP

J-Startup

locale

market

industry

website

linkedin

peer of

Metrics